Bladder Cancer

Prospective Assessment of VI-RADS with Muscle Invasion in Urinary Bladder Cancer and Its Implication on Re-Resection/Restaging TURBT Patients. November 8, 2024

The role of re-transurethral resection of bladder tumor in patients with TaHG non muscle invasive bladder cancer. November 8, 2024

Evaluating the Clinical Impact of Ureteral Frozen Section Analysis During Radical Cystectomy: A Single-Center Retrospective Study. November 7, 2024

Smoking behavior and the risks of tumor recurrence and progression in patients with non-muscle-invasive bladder cancer. November 7, 2024

DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. November 7, 2024

Prototol for the Prospective Sample Collection for Cancer of Bladder (ProCaB) Trial by the Cancer of the Bladder Leuven (CaBLe) Consortium. November 6, 2024

A Molecular Urine Assay to Detect Recurrences During Surveillance of High-Risk Non-Muscle Invasive Bladder Cancer. November 6, 2024

Deciphering the molecular heterogeneity of intermediate- and (very-)high-risk non-muscle-invasive bladder cancer using multi-layered -omics studies. November 6, 2024

Single-Cell Transcriptomic Analysis to Build a Microenvironment-Aware Bladder Cancer Prognostic Model - Expert Commentary November 5, 2024

Perioperative Use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now. November 5, 2024

Lifestyle Advice to Patients with Bladder Cancer: A National Survey of Dutch Urologists. November 5, 2024

Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer. November 5, 2024

Distinct Gene Expression Patterns Identify Patients who Relapse After Neoadjuvant Pembrolizumab and Radical Cystectomy in the PURE-01 Study. November 5, 2024

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC November 4, 2024

ACR Appropriateness Criteria® Pretreatment Staging of Urothelial Cancer: 2024 Update. November 4, 2024

Prehabilitative/rehabilitative exercise, nutrition, and psychological support for bladder cancer: A scoping review of randomized clinical trials. November 4, 2024

Modulation of the tumor microenvironment in non-muscle-invasive bladder cancer by OncoTherad® (MRB-CFI-1) nanoimmunotherapy: effects on tumor-associated macrophages, tumor-infiltrating lymphocytes, and monoamine oxidases. November 4, 2024

Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer. November 4, 2024

Efficacy and Safety of Sacituzumab Govitecan in Cisplatin-Ineligible Patients with Metastatic Urothelial Cancer After Immunotherapy - Expert Commentary November 1, 2024

Prehabilitation in patients undergoing bladder cancer surgery - A systematic review and meta-analysis. November 1, 2024

Page 1 of 519